文献速递淋巴瘤造血干细胞移植与细胞治疗

经验证的综合合并症指数可预测弥漫性大B细胞淋巴瘤患者CAR-T细胞治疗的结局

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

该研究基于9个学术中心577例复发/难治性弥漫性大B细胞淋巴瘤患者建立学习队列,通过随机生存森林模型筛选出呼吸、上消化道、肝脏或肾脏系统存在严重合并症(CIRS评分≥3)的「Severe4」指数;在控制既往治疗线数、ECOG体能状态、BCL6易位和分子亚型后,Severe4在学习队列和独立单中心验证队列中均与更短的无进展生存和总生存强相关,并在学习队列中显著预测≥3级细胞因子释放综合征。

要点

  • Severe4指呼吸、上消化道、肝脏或肾脏系统CIRS评分≥3的严重合并症。
  • Severe4在学习队列和独立单中心验证队列中均与更短PFS和OS强相关。
  • Severe4在学习队列中显著预测≥3级细胞因子释放综合征,验证队列中维持该趋势。

核心结论

  • 结果表明,拟接受CAR-T细胞治疗的弥漫性大B细胞淋巴瘤患者的不良结局可通过简化的CIRS衍生合并症指数进行预测。

研究设计与样本

  • 回顾性识别9个学术中心577例拟接受CAR-T细胞治疗的复发/难治性弥漫性大B细胞淋巴瘤患者组成学习队列。
  • 对总生存和无进展生存进行随机生存森林建模,以确定影响最大的CIRS器官系统和严重程度分级。
  • 另设独立单中心验证队列。

主要发现

  • 呼吸、上消化道、肝脏或肾脏系统存在严重合并症(CIRS评分≥3)即「Severe4」,对CAR-T后生存影响最大。
  • 控制既往治疗线数、ECOG体能状态、BCL6易位和分子亚型后,Severe4在学习队列和独立单中心验证队列中均与更短PFS和OS强相关。
  • Severe4在学习队列中显著预测≥3级细胞因子释放综合征,在验证队列中维持该趋势。

关键数值与推荐

  • Severe4定义为呼吸、上消化道、肝脏或肾脏系统中任一系统CIRS评分≥3。
  • 控制因素包括既往治疗线数、ECOG体能状态、BCL6易位和分子亚型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of response and prevalent toxicities remain problematic. Identifying patients who are at high risk of disease progression, toxicity, and death would inform treatment decisions. Although the cumulative illness rating scale (CIRS) has been shown to correlate with survival in B-cell malignancies, no prognostic score has been independently validated in CART recipients. We retrospectively identified 577 patients with relapsed/refractory DLBCL indicated for CART at 9 academic centers to form a learning cohort (LC). Random survival forest modeling of overall survival (OS) and progression-free survival (PFS) was performed to determine the most influential CIRS organ systems and severity grades. The presence of a severe comorbidity (CIRS score ≥ 3) in the respiratory, upper gastrointestinal, hepatic, or renal system, herein termed "Severe4," had the greatest impact on post-CART survival. Controlling for other prognostic factors (number of prior therapies, Eastern Cooperative Oncology Group performance status, BCL6 translocation, and molecular subtype), Severe4 was strongly associated with shorter PFS and OS in the LC and in an independent single-center validation cohort (VC). Severe4 was also a significant predictor of grade ≥3 cytokine release syndrome in the LC, while maintaining this trend in the VC. Thus, our results indicate that adverse outcomes for patients with DLBCL meant to receive CART can be predicted using a simplified CIRS-derived comorbidity index.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shouse G, Kaempf A, Gordon MJ, et al. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023. PMID: 36735393. doi:10.1182/bloodadvances.2022009309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。